Skip to main content
Erschienen in: Langenbeck's Archives of Surgery 4/2008

01.07.2008 | Original Article

The tobacco carcinogen NNK is stereoselectively reduced by human pancreatic microsomes and cytosols

verfasst von: Neil Trushin, Gerhard Leder, Karam El-Bayoumy, Dietrich Hoffmann, Hans G. Beger, Doris Henne-Bruns, Marco Ramadani, Bogdan Prokopczyk

Erschienen in: Langenbeck's Archives of Surgery | Ausgabe 4/2008

Einloggen, um Zugang zu erhalten

Abstract

Background/aims

Cigarette smoking increases the risk of cancer of the pancreas. The tobacco-specific nitrosamine 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone (NNK) is the only known environmental compound that induces pancreatic cancer in laboratory animals. Concentrations of NNK are significantly higher in the pancreatic juice of smokers than in that of nonsmokers. The chiral NNK metabolite, (R,S)-4-(methylnitrosamino)-1-(3-pyridyl)-1-butanol (NNAL) is itself a potent pancreatic carcinogen in rats. The carcinogenicity of NNAL is related to its stereochemistry; (S)-NNAL is a more potent lung tumorigen in the A/J mouse than is (R)-NNAL. In this study, we determined the potential of the human pancreas to convert NNK into NNAL.

Materials and methods

Human pancreatic microsomes and cytosols were incubated with [5-3H]NNK, and the metabolic products were determined by high-performance liquid chromatography (HPLC).

Results

(S)-NNAL was the predominant isomer formed in all cytosolic incubations. In ten microsomal samples, NNAL was formed at an average rate of 3.8 ± 1.6 pmol/mg/min; (R)-NNAL was the predominant isomer in this group. The average rate of NNAL formation in 18 other microsomal samples was significantly lower, 0.13 ± 0.12 pmol/mg/min (p < 0.001); (S)-NNAL was the predominant isomer formed in this group.

Conclusion

In human pancreatic tissues, there is intraindividual variability regarding the capacity for, and stereoselectivity of, carbonyl reduction of NNK.
Literatur
1.
Zurück zum Zitat Jemal A, Siegel R, Ward E, Murray T, Xu J, Smigal C, Thun MJ (2006) Cancer statistics, 2006. CA Cancer J Clin 56:106–130PubMedCrossRef Jemal A, Siegel R, Ward E, Murray T, Xu J, Smigal C, Thun MJ (2006) Cancer statistics, 2006. CA Cancer J Clin 56:106–130PubMedCrossRef
2.
Zurück zum Zitat Gallicchio L, Kouzis A, Genkinger JM, Burke AE, Hoffman SC, Diener-West M, Helzlsouer KJ, Comstock GW, Alberg AJ (2006) Active cigarette smoking, household passive smoke exposure, and the risk of developing pancreatic cancer. Prev Med 42:200–205PubMedCrossRef Gallicchio L, Kouzis A, Genkinger JM, Burke AE, Hoffman SC, Diener-West M, Helzlsouer KJ, Comstock GW, Alberg AJ (2006) Active cigarette smoking, household passive smoke exposure, and the risk of developing pancreatic cancer. Prev Med 42:200–205PubMedCrossRef
3.
Zurück zum Zitat Shen M, Boffetta P, Olsen JH, Andersen A, Hemminki K, Pukkala E, Tracey E, Brewster DH, McBride ML, Pompe-Kirn V, Kliewer EV, Tonita JM, Chia KS, Martos C, Jonasson JG, Colin D, Scelo G, Brennan P (2006) A pooled analysis of second primary pancreatic cancer. Am J Epidemiol 163:502–511PubMedCrossRef Shen M, Boffetta P, Olsen JH, Andersen A, Hemminki K, Pukkala E, Tracey E, Brewster DH, McBride ML, Pompe-Kirn V, Kliewer EV, Tonita JM, Chia KS, Martos C, Jonasson JG, Colin D, Scelo G, Brennan P (2006) A pooled analysis of second primary pancreatic cancer. Am J Epidemiol 163:502–511PubMedCrossRef
4.
Zurück zum Zitat Chiu BCH, Lynch CF, Cerhan JR, Cantor KP (2001) Cigarette smoking and risk of bladder, pancreas, kidney, and colorectal cancers in Iowa. Ann Epidemiol 11:28–37PubMedCrossRef Chiu BCH, Lynch CF, Cerhan JR, Cantor KP (2001) Cigarette smoking and risk of bladder, pancreas, kidney, and colorectal cancers in Iowa. Ann Epidemiol 11:28–37PubMedCrossRef
5.
Zurück zum Zitat Coughlin SS, Calle EE, Patel AV, Thun MJ (2000) Predictors of pancreatic cancer mortality among a large cohort of United States adults. Cancer Causes Control 11:915–923PubMedCrossRef Coughlin SS, Calle EE, Patel AV, Thun MJ (2000) Predictors of pancreatic cancer mortality among a large cohort of United States adults. Cancer Causes Control 11:915–923PubMedCrossRef
6.
Zurück zum Zitat Wynder EL, Mabuchi K, Maruchi N, Fortner JG (1973) A case control study of cancer of the pancreas. Cancer 31:641–648PubMedCrossRef Wynder EL, Mabuchi K, Maruchi N, Fortner JG (1973) A case control study of cancer of the pancreas. Cancer 31:641–648PubMedCrossRef
7.
Zurück zum Zitat Muscat JE, Stellman SD, Hoffmann D, Wynder EL (1997) Smoking and pancreatic cancer in men and women. Cancer Epidemiol Biomark Prev 6:15–19 Muscat JE, Stellman SD, Hoffmann D, Wynder EL (1997) Smoking and pancreatic cancer in men and women. Cancer Epidemiol Biomark Prev 6:15–19
8.
Zurück zum Zitat Ghadirian P, Simard A, Baillargeon J (1991) Tobacco, alcohol, and coffee and cancer of the pancreas. A population-based, case control study in Quebec, Canada. Cancer 67:2664–2670PubMedCrossRef Ghadirian P, Simard A, Baillargeon J (1991) Tobacco, alcohol, and coffee and cancer of the pancreas. A population-based, case control study in Quebec, Canada. Cancer 67:2664–2670PubMedCrossRef
9.
Zurück zum Zitat Kahn HA (1966) The Dorn study of smoking and mortality among U.S. veterans: report on eight and one-half years of observation. Natl Cancer Inst Monogr 19:1–125PubMed Kahn HA (1966) The Dorn study of smoking and mortality among U.S. veterans: report on eight and one-half years of observation. Natl Cancer Inst Monogr 19:1–125PubMed
10.
Zurück zum Zitat Hoffmann D, Hoffmann I, El-Bayoumy K (2001) The less harmful cigarette: a controversial issue. A tribute to Ernst L. Wynder. Chem Res Toxicol 14:767–790PubMedCrossRef Hoffmann D, Hoffmann I, El-Bayoumy K (2001) The less harmful cigarette: a controversial issue. A tribute to Ernst L. Wynder. Chem Res Toxicol 14:767–790PubMedCrossRef
11.
Zurück zum Zitat Hecht SS (1998) Biochemistry, biology, and carcinogenicity of tobacco-specific N-nitrosamines. Chem Res Toxicol 11:559–603PubMedCrossRef Hecht SS (1998) Biochemistry, biology, and carcinogenicity of tobacco-specific N-nitrosamines. Chem Res Toxicol 11:559–603PubMedCrossRef
12.
Zurück zum Zitat Hoffmann D, Rivenson A, Abbi R, Wynder EL (1993) A study of tobacco carcinogenesis: effect of the fat content of the diet on the carcinogenic activity of 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone in F344 rats. Cancer Res 53:2758–2761PubMed Hoffmann D, Rivenson A, Abbi R, Wynder EL (1993) A study of tobacco carcinogenesis: effect of the fat content of the diet on the carcinogenic activity of 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone in F344 rats. Cancer Res 53:2758–2761PubMed
13.
Zurück zum Zitat Rivenson A, Hoffmann D, Prokopczyk B, Amin S, Hecht SS (1988) Induction of lung and exocrine pancreas tumors in F344 rats by tobacco-specific and Areca-derived N-nitrosamines. Cancer Res 48:6912–6917PubMed Rivenson A, Hoffmann D, Prokopczyk B, Amin S, Hecht SS (1988) Induction of lung and exocrine pancreas tumors in F344 rats by tobacco-specific and Areca-derived N-nitrosamines. Cancer Res 48:6912–6917PubMed
14.
Zurück zum Zitat Ouyang H, Mou L-j, Luk C, Liu N, Karaskova J, Squire J, Tsao M-S (2000) Immortal human pancreatic duct epithelial cell lines with near normal genotype and phenotype. Am J Pathol 157:1623–1631PubMed Ouyang H, Mou L-j, Luk C, Liu N, Karaskova J, Squire J, Tsao M-S (2000) Immortal human pancreatic duct epithelial cell lines with near normal genotype and phenotype. Am J Pathol 157:1623–1631PubMed
15.
Zurück zum Zitat Prokopczyk B, Hoffmann D, Bologna M, Cunningham AJ, Trushin N, Akerkar S, Boyiri T, Amin S, Desai D, Colosimo S, Pittman B, Leder G, Ramadani M, Henne-Bruns D, Beger HG, El-Bayoumy K (2002) Identification of tobacco-derived compounds in human pancreatic juice. Chem Res Toxicol 15:677–685PubMedCrossRef Prokopczyk B, Hoffmann D, Bologna M, Cunningham AJ, Trushin N, Akerkar S, Boyiri T, Amin S, Desai D, Colosimo S, Pittman B, Leder G, Ramadani M, Henne-Bruns D, Beger HG, El-Bayoumy K (2002) Identification of tobacco-derived compounds in human pancreatic juice. Chem Res Toxicol 15:677–685PubMedCrossRef
16.
Zurück zum Zitat Hecht SS, Carmella SG, Murphy SE, Akerkar S, Brunnemann K, Hoffmann D (1993) A tobacco-specific lung carcinogen in the urine of men exposed to cigarette smoke. N Engl J Med 329:1543–1546PubMedCrossRef Hecht SS, Carmella SG, Murphy SE, Akerkar S, Brunnemann K, Hoffmann D (1993) A tobacco-specific lung carcinogen in the urine of men exposed to cigarette smoke. N Engl J Med 329:1543–1546PubMedCrossRef
17.
Zurück zum Zitat Carmella SG, Akerkar SA, Richie JP, Hecht SS (1995) Intraindividual and interindividual differences in metabolites of the tobacco-specific lung carcinogen 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone (NNK) in smokers’ urine. Cancer Epidemiol Biomark Prev 4:635–642 Carmella SG, Akerkar SA, Richie JP, Hecht SS (1995) Intraindividual and interindividual differences in metabolites of the tobacco-specific lung carcinogen 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone (NNK) in smokers’ urine. Cancer Epidemiol Biomark Prev 4:635–642
18.
Zurück zum Zitat Upadhyaya P, Kenney PMJ, Hochalter JB, Wang M, Hecht SS (1999) Tumorigenicity and metabolism of 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanol enantiomers and metabolites in the A/J mouse. Carcinogenesis 20:1577–1582PubMedCrossRef Upadhyaya P, Kenney PMJ, Hochalter JB, Wang M, Hecht SS (1999) Tumorigenicity and metabolism of 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanol enantiomers and metabolites in the A/J mouse. Carcinogenesis 20:1577–1582PubMedCrossRef
19.
Zurück zum Zitat Staretz ME, Murphy SE, Patten CJ, Nunes MG, Koehl W, Amin S, Koenig LA, Guengerich FP, Hecht SS (1997) Comparative metabolism of the tobacco-related carcinogens benzo[a]pyrene, 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone, 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanol and N′-nitrosonornicotine in human hepatic microsomes. Drug Metab Dispos 25:154–162PubMed Staretz ME, Murphy SE, Patten CJ, Nunes MG, Koehl W, Amin S, Koenig LA, Guengerich FP, Hecht SS (1997) Comparative metabolism of the tobacco-related carcinogens benzo[a]pyrene, 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone, 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanol and N′-nitrosonornicotine in human hepatic microsomes. Drug Metab Dispos 25:154–162PubMed
20.
Zurück zum Zitat Chen CB, Hecht SS, Hoffmann D (1978) Metabolic α-hydroxylation of the tobacco-specific carcinogen, N′-nitrosonornicotine. Cancer Res 38:3639–3645PubMed Chen CB, Hecht SS, Hoffmann D (1978) Metabolic α-hydroxylation of the tobacco-specific carcinogen, N′-nitrosonornicotine. Cancer Res 38:3639–3645PubMed
21.
Zurück zum Zitat McKennis H, Schwartz SL, Turnbull LB, Tamaki E, Bowman ER (1964) Metabolic formation of gamma-(3-pyridyl)-gamma-hydroxybutyric acid and its possible intermediary role in mammalian metabolism of nicotine. J Biol Chem 239:3981–3989PubMed McKennis H, Schwartz SL, Turnbull LB, Tamaki E, Bowman ER (1964) Metabolic formation of gamma-(3-pyridyl)-gamma-hydroxybutyric acid and its possible intermediary role in mammalian metabolism of nicotine. J Biol Chem 239:3981–3989PubMed
22.
Zurück zum Zitat Prokopczyk B, Trushin N, Leszczynska J, Waggoner SE, El-Bayoumy K (2001) Human cervical tissue metabolizes the tobacco-specific nitrosamine, 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone, via α-hydroxylation and carbonyl reduction pathways. Carcinogenesis 22:107–114PubMedCrossRef Prokopczyk B, Trushin N, Leszczynska J, Waggoner SE, El-Bayoumy K (2001) Human cervical tissue metabolizes the tobacco-specific nitrosamine, 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone, via α-hydroxylation and carbonyl reduction pathways. Carcinogenesis 22:107–114PubMedCrossRef
23.
Zurück zum Zitat Smith TJ, Stoner GD, Yang CS (1995) Activation of 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone (NNK) in human lung microsomes by cytochromes P450, lipoxygenase, and hydroperoxides. Cancer Res 55:5566–5573PubMed Smith TJ, Stoner GD, Yang CS (1995) Activation of 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone (NNK) in human lung microsomes by cytochromes P450, lipoxygenase, and hydroperoxides. Cancer Res 55:5566–5573PubMed
24.
Zurück zum Zitat Hecht SS, Spratt TE, Trushin N (1997) Absolute configuration of 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanol formed metabolically from 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone. Carcinogenesis 18:1851–1854PubMedCrossRef Hecht SS, Spratt TE, Trushin N (1997) Absolute configuration of 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanol formed metabolically from 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone. Carcinogenesis 18:1851–1854PubMedCrossRef
25.
Zurück zum Zitat Hecht SS, Spratt TE, Trushin N (2000) Corrigendum: Absolute configuration of 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanol formed metabolically from 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone. Carcinogenesis 20:850 Hecht SS, Spratt TE, Trushin N (2000) Corrigendum: Absolute configuration of 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanol formed metabolically from 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone. Carcinogenesis 20:850
26.
Zurück zum Zitat Maser E (1998) 11β-Hydroxysteroid dehydrogenase responsible for carbonyl reduction of the tobacco-specific nitrosamine 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone in mouse lung microsomes. Cancer Res 58:2996–2303PubMed Maser E (1998) 11β-Hydroxysteroid dehydrogenase responsible for carbonyl reduction of the tobacco-specific nitrosamine 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone in mouse lung microsomes. Cancer Res 58:2996–2303PubMed
27.
Zurück zum Zitat Zimmerman CL, Wu Z, Upadhyaya P, Hecht SS (2004) Stereoselective metabolism and tissue retention in rats of the individual enantiomers of 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanol (NNAL), metabolites of the tobacco-specific nitrosamine, 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone (NNK). Carcinogenesis 25:1237–1242PubMedCrossRef Zimmerman CL, Wu Z, Upadhyaya P, Hecht SS (2004) Stereoselective metabolism and tissue retention in rats of the individual enantiomers of 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanol (NNAL), metabolites of the tobacco-specific nitrosamine, 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone (NNK). Carcinogenesis 25:1237–1242PubMedCrossRef
28.
Zurück zum Zitat Lao YB, Yu NX, Kassie F, Villalta PW, Hecht SS (2007) Formation and accumulation of pyridyloxobutyl DNA adducts in F344 rats chronically treated with 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone and enantiomers of its metabolite, 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanol. Chem Res Toxicol 20:235–245CrossRef Lao YB, Yu NX, Kassie F, Villalta PW, Hecht SS (2007) Formation and accumulation of pyridyloxobutyl DNA adducts in F344 rats chronically treated with 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone and enantiomers of its metabolite, 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanol. Chem Res Toxicol 20:235–245CrossRef
29.
Zurück zum Zitat Soldan M, Nagel G, Losekam M, Ernst M, Maser E (1999) Interindividual variability in the expression and NNK carbonyl reductase activity of 11β-hydroxysteroid dehydrogenase 1 in human lung. Cancer Lett 145:49–56PubMedCrossRef Soldan M, Nagel G, Losekam M, Ernst M, Maser E (1999) Interindividual variability in the expression and NNK carbonyl reductase activity of 11β-hydroxysteroid dehydrogenase 1 in human lung. Cancer Lett 145:49–56PubMedCrossRef
30.
Zurück zum Zitat Anderson KE, Hammons GJ, Kadlubar FF, Potter JD, Kaderlik KR, Ilett KF, Minchin RF, Teitel CH, Chou HC, Martin MV, Guengerich FP, Barone GW, Lang NP, Peterson LA (1997) Metabolic activation of aromatic amines by human pancreas. Carcinogenesis 18:1085–1092PubMedCrossRef Anderson KE, Hammons GJ, Kadlubar FF, Potter JD, Kaderlik KR, Ilett KF, Minchin RF, Teitel CH, Chou HC, Martin MV, Guengerich FP, Barone GW, Lang NP, Peterson LA (1997) Metabolic activation of aromatic amines by human pancreas. Carcinogenesis 18:1085–1092PubMedCrossRef
31.
Zurück zum Zitat Prokopczyk B, Leder G, Trushin N, Cunningham AJ, Akerkar S, Pittman B, Ramadani M, Straeter J, Beger HG, Henne-Bruns D, El-Bayoumy K (2005) 4-Hydroxy-1-(3-pyridyl)-1-butanone, an indicator for 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone-induced DNA damage, is not detected in human pancreatic tissue. Cancer Epidemiol Biomark Prev 14:540–541CrossRef Prokopczyk B, Leder G, Trushin N, Cunningham AJ, Akerkar S, Pittman B, Ramadani M, Straeter J, Beger HG, Henne-Bruns D, El-Bayoumy K (2005) 4-Hydroxy-1-(3-pyridyl)-1-butanone, an indicator for 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone-induced DNA damage, is not detected in human pancreatic tissue. Cancer Epidemiol Biomark Prev 14:540–541CrossRef
Metadaten
Titel
The tobacco carcinogen NNK is stereoselectively reduced by human pancreatic microsomes and cytosols
verfasst von
Neil Trushin
Gerhard Leder
Karam El-Bayoumy
Dietrich Hoffmann
Hans G. Beger
Doris Henne-Bruns
Marco Ramadani
Bogdan Prokopczyk
Publikationsdatum
01.07.2008
Verlag
Springer-Verlag
Erschienen in
Langenbeck's Archives of Surgery / Ausgabe 4/2008
Print ISSN: 1435-2443
Elektronische ISSN: 1435-2451
DOI
https://doi.org/10.1007/s00423-007-0265-3

Weitere Artikel der Ausgabe 4/2008

Langenbeck's Archives of Surgery 4/2008 Zur Ausgabe

Update Chirurgie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

S3-Leitlinie „Diagnostik und Therapie des Karpaltunnelsyndroms“

Karpaltunnelsyndrom BDC Leitlinien Webinare
CME: 2 Punkte

Das Karpaltunnelsyndrom ist die häufigste Kompressionsneuropathie peripherer Nerven. Obwohl die Anamnese mit dem nächtlichen Einschlafen der Hand (Brachialgia parästhetica nocturna) sehr typisch ist, ist eine klinisch-neurologische Untersuchung und Elektroneurografie in manchen Fällen auch eine Neurosonografie erforderlich. Im Anfangsstadium sind konservative Maßnahmen (Handgelenksschiene, Ergotherapie) empfehlenswert. Bei nicht Ansprechen der konservativen Therapie oder Auftreten von neurologischen Ausfällen ist eine Dekompression des N. medianus am Karpaltunnel indiziert.

Prof. Dr. med. Gregor Antoniadis
Berufsverband der Deutschen Chirurgie e.V.

S2e-Leitlinie „Distale Radiusfraktur“

Radiusfraktur BDC Leitlinien Webinare
CME: 2 Punkte

Das Webinar beschäftigt sich mit Fragen und Antworten zu Diagnostik und Klassifikation sowie Möglichkeiten des Ausschlusses von Zusatzverletzungen. Die Referenten erläutern, welche Frakturen konservativ behandelt werden können und wie. Das Webinar beantwortet die Frage nach aktuellen operativen Therapiekonzepten: Welcher Zugang, welches Osteosynthesematerial? Auf was muss bei der Nachbehandlung der distalen Radiusfraktur geachtet werden?

PD Dr. med. Oliver Pieske
Dr. med. Benjamin Meyknecht
Berufsverband der Deutschen Chirurgie e.V.

S1-Leitlinie „Empfehlungen zur Therapie der akuten Appendizitis bei Erwachsenen“

Appendizitis BDC Leitlinien Webinare
CME: 2 Punkte

Inhalte des Webinars zur S1-Leitlinie „Empfehlungen zur Therapie der akuten Appendizitis bei Erwachsenen“ sind die Darstellung des Projektes und des Erstellungswegs zur S1-Leitlinie, die Erläuterung der klinischen Relevanz der Klassifikation EAES 2015, die wissenschaftliche Begründung der wichtigsten Empfehlungen und die Darstellung stadiengerechter Therapieoptionen.

Dr. med. Mihailo Andric
Berufsverband der Deutschen Chirurgie e.V.